ArticleCancer medicine2022
The efficacy of low-power cumulative high-intensity focused ultrasound treatment for recurrent desmoid tumor.
Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension: A Pilot Study.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Local Treatment of Desmoid Tumors: An Update.Seminars in interventional radiology · 2024Review
- Ultrasound-guided peripheral nerve blockade in high-intensity focused ultrasound ablation for extra-abdominal desmoid tumors: a case series.Quantitative imaging in medicine and surgery · 2024Article
- Initial treatment for surgery-naïve desmoid tumors by high intensity focused ultrasound.Frontiers in oncology · 2024Article
- Efficacy and safety of different thermal ablative therapies for desmoid-type fibromatosis: a systematic review and meta-analysis.Quantitative imaging in medicine and surgery · 2023Article
- Role of the Interventional Radiologist in the Treatment of Desmoid Tumors.Life (Basel, Switzerland) · 2023Review
- Novel insights into biomarkers of progression in Desmoid tumor.Frontiers in oncology · 2023Review
- Case Report: Desmoid tumor response to magnetic resonance-guided high intensity focused ultrasound over 4 years.Frontiers in oncology · 2023Article
- Case report: Intra-abdominal aggressive fibromatosis: A rare cause of hyperemesis.Frontiers in surgery · 2023Article
- The efficacy of low-power cumulative high-intensity focused ultrasound treatment for recurrent desmoid tumor.Cancer medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDesmoid tumors are rare neoplasms that are locally invasive. However, optimal treatment strategies for recurrent desmoid tumors remain controversial. High-intensity focused ultrasound (HIFU) has been reported as a noninvasive modality for treating recurrent desmoid tumors. However, its efficacy against massive desmoid tumors or those with complex anatomies remains unclear.
methodsWe developed a new therapeutic strategy called low-power cumulative HIFU and applied it to treat recurrent desmoid tumors.
resultsWe retrospectively collected data from 91 patients with recurrent desmoid tumors who underwent low-power cumulative HIFU treatment after surgical treatment failure. The mean ablation proportion of the HIFU treatment was 69.5%, and the objective response rate was 47.3%. The 5-year estimated progression-free survival rate for these patients was 69.3%.
conclusionLow-power cumulative HIFU treatment could achieve significant efficacy and long-term control of recurrent desmoid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.